Form 4: Rani Therapeutics Director Jean-Luc Butel Granted 50,000 Stock Options

Rani Therapeutics Holdings, Inc. (RANI) disclosed that Director Jean-Luc Butel was granted 50,000 stock options with an exercise price of $0.62 per share.

Summary

• Jean-Luc Butel, a Director of Rani Therapeutics Holdings, Inc. (RANI), acquired 50,000 Director Stock Options on May 28, 2025.
• The options have an exercise price of $0.62 per share.
• The expiration date for these options is May 27, 2035.
• The shares underlying the option are Class A Common Stock, totaling 50,000 shares.
• The options vest in full on the first anniversary of the grant date (May 28, 2026), subject to Mr. Butel's continuous service.
• Accelerated vesting will occur upon the Company's next annual stockholder meeting or a Change in Control, as defined in the Company's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholder value, which is generally viewed favorably. However, it's a routine compensation event, not a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the stock price increases.
• The exercise price of $0.62 per share is relatively low, suggesting a potential incentive for the director to contribute to significant share price appreciation.

Future Outlook

The vesting schedule for the granted options indicates future milestones that could trigger accelerated vesting, specifically the Company's next annual stockholder meeting or a Change in Control, aligning the director's incentives with these potential future events.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align the interests of board members with company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, including a one-year cliff and accelerated vesting upon specific corporate events (annual meeting, change in control), is also a common structure for equity awards to non-employee directors, comparable to practices seen in companies like Moderna or BioNTech for their board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jean-Luc Butel, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also improved alignment of director's interests with shareholder value creation.
• Director (Jean-Luc Butel): Receives equity-based compensation, incentivizing long-term commitment and performance.

Next Steps

• The options will vest on the first anniversary of the grant date (May 28, 2026), or earlier upon the Company's next annual stockholder meeting or a Change in Control.
• Following vesting, the director may choose to exercise the options to acquire Class A Common Stock.

Key Dates

Keywords

Rani Therapeutics, RANI, Form 4, stock option, insider transaction, director compensation, equity incentive, beneficial ownership